March 24 (Reuters) - Fevertree Drinks posted on Tuesday a 16% drop in annual profit, as the initial impact of its U.S. partnership with Molson Coors weighed on overall margins. The company reported
Fever-Tree Drinks' profit drops 16% on Molson Coors' partnership impact, packaging levy dispute
Fever-Tree Drinks Faces Profit Decline Amid Regulatory and Partnership Challenges
March 24 (Reuters) - Fever-Tree Drinks reported a 16% drop in annual profit on Tuesday after booking a one-off 2.8-million-pound ($3.76 million) charge over a disputed packaging levy and facing margin pressure from its U.S. partnership with Molson Coors.
Legal Dispute Over Packaging Levy
The company said it has launched a formal legal challenge against the UK Environment Agency over the Extended Producer Responsibility levy, which Fever-Tree argues should not apply to certain glass formats sold in bars and restaurants.
Industry-Wide Impact of Environmental Regulations
Fever-Tree is the latest British company to clash with regulators over new environmental packaging rules that shift recycling costs onto producers, adding to the broader cost pressures weighing on profitability.
Analyst Commentary on Provision
"The decision to take a provision to cover a possible additional EPR liability represents accounting prudence rather than any change in Fever-Tree's confidence in its position," Matthew Webb, an Investec Bank analyst noted.
Fever-Tree shares fell 5.7% in early trade, but reversed course to trade 2.8% higher by 0850 GMT.
Molson Coors Deal and U.S. Market Performance
MOLSON COORS DEAL
Fever-Tree, which manufactures most of the products it sells in the U.S. in Britain, signed a distribution and manufacturing agreement with Molson Coors last year to help localise production amid rising tariffs and boost its U.S. sales.
Growth in U.S. Revenue
The tonic maker's U.S. revenue, which accounts for about one-third of the total, grew 6% on a constant-currency basis in 2025.
CEO and Analyst Perspectives on U.S. Partnership
CEO Tim Warrillow said the strategic partnership creates "a significant opportunity to take Fever-Tree to the next level" in its largest growth market, adding that the company remains comfortable with market expectations for 2026.
"2026 will start to show the benefits of the TAP deal with a major uplift in scale and execution capability in the US," Jefferies analysts said, adding that they expect sales to pick up toward the end of the first half and gather further momentum in the second half.
Financial Results and Market Expectations
Fever-Tree reported adjusted core profit of 42.4 million pounds, down from 50.7 million pounds last year. Analysts' expectations, on average, were at 44.4 million pounds, according to a company-compiled poll.
($1 = 0.7449 pounds)
(Reporting by Yamini Kalia in Bengaluru; Editing by Sherry Jacob-Phillips and Louise Heavens)
